ASH 2022 | Update on Phase I/II study of glofitamab monotherapy in R/R MCL
Tycel Phillips, MD, City of Hope, Duarte, CA, gives an update on a Phase I/II study that evaluated glofitamab monotherapy with step-up dosing and obinutuzumab pretreatment in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL; NCT03075696). As Dr Phillips explains, this study suggests that fixed-duration glofitamab induces durable complete remission (CR) rates, and was associated with mostly low-grade and manageable cytokine release syndrome (CRS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Abbvie, AstraZeneca, Bayer, Beigene, BMS, Eli Lily, Epizyme, Genmab, Genentech, Gilead, Incyte, Pharmacyclics, Xencor Research support from Abbvie, Bayer, BMS, Incyte
